471 patents
Page 16 of 24
Utility
Tissue Factor Pathway Inhibitor Antibodies and Uses Thereof
8 Apr 21
The invention relates to antibodies, and antigen-binding fragments thereof, that specifically bind TFPI and inhibit an activity thereof.
Debra Pittman, James R. Apgar, Zong Sean Juo, Macy Jin, Mark Stahl, Gregory J. Carven, Matthew Holsti, Susan Benard, Sunita R. Hett, Reema Jasuja
Filed: 24 Nov 20
Utility
Coformer Salts of (2S,3S)-METHYL 7-FLUORO-2-(4-FLUOROPHENYL)-3-(1-METHYL-1H-1,2,4-TRIAZOL-5-YL)-4-OXO-1,2,3,4-TETRAHYDROQUINOLINE-5-CARBOXYLATE and Methods of Preparing Them
1 Apr 21
Described herein are coformer salts of (2S,3S)-methyl 7-fluoro-2-(4-fluorophenyl)-3-(1-methyl-1H-1,2,4-triazol-5-yl)-4-oxo-1,2,3,4-tetrahydroquinoline-5-carboxylate optionally as a solvate and additionally optionally as a hydrate, including crystalline forms, and methods of preparing the (2S,3S)-methyl 7-fluoro-2-(4-fluorophenyl)-3-(1-methyl-1H-1,2,4-triazol-5-yl)-4-oxo-1,2,3,4-teirahydroquinoline-5-carboxylate optionally as a coformer salts.
Mark HENDERSON, Colm CAMPBELL, Carsten JAGUSCH, Christian Klaus HERZ, Nico BAUER, Thierry BONNAUD, Olivier LAMBERT
Filed: 10 Aug 20
Utility
Neisseria Meningitidis Compositions and Methods Thereof
25 Mar 21
In one aspect, the invention relates to a composition including a first polypeptide having the sequence set forth in SEQ ID NO: 1 and a second polypeptide having the sequence set forth in SEQ ID NO: 2.
Kathrin Ute Jansen, Annaliesa Sybil Anderson, Rasappa Gounder Arumugham, John Erwin Farley, Leah Diane Fletcher, Shannon Lea Harris, Thomas Richard Jones, Lakshmi Khandke, Bounthon Loun, John Lance Perez, Gary Warren Zlotnick
Filed: 8 Dec 20
Utility
Modulators of STING (Stimulator of Interferon Genes)
25 Mar 21
Ryan PATMAN, Martin James WYTHES, Eugene Yuanjin RUI, Indrawan James MCALPINE, Andrew FENSOME, Mehran JALAIE, Ketan S. GAJIWALA, Chan Woo HUH, Tuan Phong TRAN, Lei ZHANG, Dahui ZHOU, Ethan Lawrence FISHER
Filed: 23 Sep 20
Utility
BCKDK Inhibitors
25 Mar 21
Samit Kumar Bhattacharya, Leanne Marie Buzon, Kevin James Filipski, David Andrew Griffith, Bethany Lyn Kormos, Luis Angel Martinez-Alsina, Russell Alan Miller, Matthew Richard Reese, Rachel Jane Roth Flach, Yuan Zhang
Filed: 23 Oct 20
Utility
Methods and Combination Therapy to Treat Cancer
18 Mar 21
This invention relates to a method of treating cancer by administering a combination therapy comprising a combination of a MEK inhibitor and a PD-1 axis binding antagonist, or a combination of a MEK inhibitor and a PARP inhibitor, or a combination of a MEK inhibitor and a PD-1 axis binding antagonist and a PARP inhibitor to a patient in need thereof.
Christoffel Hendrik Boshoff, Rossano Cesari, Cristian Massacesi, Nuzhat Pathan, Patrice A. Lee, Shannon L. Winski
Filed: 17 Dec 18
Utility
Polymorphs of ARRY-380, a Selective HER2 Inhibitor and Pharmaceutical Compositions Containing Them
18 Mar 21
Polymorphs of N4-(4-([1,2,4]triazolo[1,5 -a]pyridin-7-yloxy)-3 -methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine are provided herein.
Donald T. Corson, Christopher M. Lindemann, Daniel J. Watson
Filed: 29 Jul 20
Utility
Treatment of Breast Cancer
11 Mar 21
The disclosure describes compounds useful for treating breast cancers.
Andrew A. Protter, Jennifer Richer, Dawn Cochrane
Filed: 22 Jan 20
Utility
Boron Containing PDE4 Inhibitors
11 Mar 21
Joseph Walter Strohbach, Tsutomu Akama, David Clive Blakemore, Robert Toms Jacobs, Peter Jones, David Christopher Limburg, Martins Sunday Oderinde, Matthew Alexander Perry, Jacob John Plattner, Rubben Federico Torella, Yasheen Zhou, Thean Yeow Yeoh
Filed: 28 Oct 20
Utility
Combination Therapy
11 Mar 21
This disclosure provides a dosage regimen for co-administration of 4-[7-[6-cyano-5-(trifluoromethyl)pyridin-3-yl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-5-yl]-2-fluoro-N-methylbenzamide and a strong CYP3A4 inducer.
Jacqueline Gibbons, Joyce Mordenti, Michiel De Vries, Walter Krauwinkel, Taoufik Ouatas
Filed: 30 Mar 20
Utility
Dihydropyridophthalazinone Inhibitors of Poly(adp-ribose)polymerase (Parp)
11 Mar 21
Bing WANG, Daniel CHU
Filed: 21 Aug 20
Utility
PD-L1 Antagonist Combination Treatments
11 Mar 21
The present disclosure describes combination therapies comprising an antagonist of Programmed Death Ligand 1 receptor (PD-L1) and another therapeutic agent, and the use of the combination therapies for the treatment of cancer.
Glen Ian ANDREWS, Shihao CHEN, Alessandra DI PIETRO, David FONTANA, Zelanna GOLDBERG, Chia-Yang LIN, Hua LONG, Marcella MARTIGNONI, Dimitry Serge Antoine NUYTEN, Aron David THALL, Adrian WOOLFSON
Filed: 19 Nov 20
Utility
Bifunctional Cytotoxic Agents Containing the Cti Pharmacophore
4 Mar 21
Andreas MADERNA, Chakrapani SUBRAMANYAM, Lawrence N. TUMEY, Zecheng CHEN, Jeffrey M. CASAVANT
Filed: 6 Nov 20
Utility
ANTI-IL-2 Antibodies and Compositions and Uses Thereof
4 Mar 21
The present invention provides antibodies, or antigen-binding portions thereof, which specifically bind to IL-2 and reduce the affinity of IL-2 binding to IL-2Rα and IL-2Rβ.
Isaac J. RONDON, Natasha Crellin, Paul Bessette, Eleonora Trotta, Jeffrey A. Bluestone, Lauren K. Ely, Kenan C. Garcia
Filed: 9 Jul 20
Utility
Orally Administered Combinations of Beta-lactam Antibiotics and Avibactam Derivatives for Treating Bacterial Infections
4 Mar 21
Pharmaceutical compositions comprising a β-lactam antibiotic and an avibactam derivative and methods of treating bacterial infections using the pharmaceutical compositions are disclosed.
JOAQUIM TRIAS, CAROLE SABLE, ANDREW NICHOLLS
Filed: 27 Aug 20
Utility
Therapeutic Antibodies and Their Uses
25 Feb 21
The present invention relates to antibodies, e.g., full length antibodies or antigen binding fragments thereof, that specifically bind to BCMA (B-Cell Maturation Antigen) and/or CD3 (Cluster of Differentiation 3).
Tracy Chia-Chien KUO, Javier Fernando CHAPARRO RIGGERS, Wei CHEN, Amy Shaw-Ru CHEN, Edward Derrick PASCUA, Thomas John VAN BLARCOM, Leila Marie BOUSTANY, Weihsien HO, Yik Andy YEUNG, Pavel STROP, Arvind RAJPAL
Filed: 27 Aug 20
Utility
GLP-1 Receptor Agonists and Uses Thereof
18 Feb 21
Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, 7-aza- and 4,7-diaza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.
Gary Erik Aspnes, Scott W. Bagley, John M. Curto, Matthew S. Dowling, David Edmonds, Mark E. Flanagan, Kentaro Futatsugi, David A. Griffith, Kim Huard, Gajendra Ingle, Wenhua Jiao, Chris Limberakis, Alan M. Mathiowetz, David W. Piotrowski, Roger B. Ruggeri
Filed: 30 Oct 20
Utility
N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS
18 Feb 21
Mary Theresa Didiuk, Robert Lee Dow, David Andrew Griffith
Filed: 28 Sep 20
Utility
Solid State Forms of (S)-2-(((S)-6,8-DIFLUORO-1,2,3,4-TETRAHYDRONAPHTHALEN-2-YL)AMINO)-N-(1-(2-METHYL-1-(NEOPENTYLAMINO)PROPAN-2-YL)-1H-IMIDAZOL-4-YL)PENTANAMIDE and Uses Thereof
11 Feb 21
The present disclosure relates to: a) solid state forms of hydrobromide salts of Compound 1; b) pharmaceutical compositions comprising one or more solid state forms of hydrobromide salts of Compound 1, and, optionally, a pharmaceutically acceptable carrier; c) methods of treating tumors or cancers by administering one or more solid state forms of hydrobromide salts of Compound 1 to a subject in need thereof; and d) methods for the preparation of solid state forms of Compound 1.
Elaine GREER, Stephen ANDERSON, Mark MALONEY, Shu YU, Ekaterina ALBERT, Emily RIGSBEE
Filed: 28 May 20
Utility
Humanized Antibodies
11 Feb 21
Disclosed herein are humanized antibodies in which human germline residues are introduces to the complementarity determining regions (CDRs) of a non-human donor antibody.
William James Jonathan Finlay, Lioudmila Tchistiakova, Eric M. Bennett
Filed: 1 Apr 20